SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-042444
Filing Date
2024-05-13
Accepted
2024-05-13 17:28:29
Documents
15
Period of Report
2024-05-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0205983-8k_estrella.htm   iXBRL 8-K 35528
2 AMENDMENT NO. 1 TO STATEMENT OF WORK NO. 001, DATED MAY 13, 2024 AND EFFECTIVE M ea0205983ex10-1_estrella.htm EX-10.1 10745
  Complete submission text file 0001213900-24-042444.txt   272090

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE esla-20240513.xsd EX-101.SCH 3863
4 XBRL DEFINITION FILE esla-20240513_def.xml EX-101.DEF 26753
5 XBRL LABEL FILE esla-20240513_lab.xml EX-101.LAB 36958
6 XBRL PRESENTATION FILE esla-20240513_pre.xml EX-101.PRE 25377
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0205983-8k_estrella_htm.xml XML 6081
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

IRS No.: 861314502 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40608 | Film No.: 24940468
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)